Prof. Dr. Vincent Bours
University Hospital of Liège & University of Liège - Liège, Belgium

Vincent Bours is Director of the Department of Medical Genetics at the CHU de Liège (University Hospital of Liège). He is an ordinary professor at the University of Liège and Vice-Chairman of the Management Committee of the National Fund for Rare Diseases and Orphan Medicinal Products.

He completed his education in hematology and oncology at the University Hospital of Liège and did research work between 1989 and 1992 at the National Institute of Health in the United States. His main clinical and research interest is in cancer genetics and familial cancer syndromes.

Prof. Dr. Michel Delforge
University Hospital Leuven & Catholic University of Leuven - Leuven, Belgium

Michel Delforge is Professor of Medicine in the Department of Hematology at the Catholic University of Leuven, Belgium. He trained in Leuven and at the University of Minnesota, USA, and obtained a doctoral degree in biomedical sciences. Dr Delforge is currently chairman of the Cancer Institute Leuven and clinical head of the Department of Hematology where he directs the plasma cell dyscrasia unit.

He is also a senior clinical investigator, chairman of the Belgian Myeloma Working Party, and active member of the Intergroupe Francophone du Myélome, HOVON (Hemato-Oncology Foundation for Adults in the Netherlands), and the International Myeloma Working Group. He holds the Luc Fraiture Chair in Hematology at the University of Leuven, and has authored or co-authored more than 100 manuscripts and several book chapters in the field of hematology.

Prof. Dr. Cedric Hermans
Saint-Luc University Hospital & Catholic University of Louvain, Belgium

Cedric Hermans currently heads the Division of Haematology, the Hemostasis and Thrombosis Unit as well as the Hemophilia Center of the Saint-Luc University Hospital in Brussels, Belgium. He was appointed Associate Professor at the Medical School of the Catholic University of Louvain in 2003, Full Professor in 2012 and Vice-Dean in 2015.

Professor Hermans has (co)-authored more than 300 publications in international journals and is a member of several scientific societies and international advisory boards and collaborative research projects. He is past-president of EAHAD, member of the Board of Directors of the World Federation of Haemophilia and the Editor-in-Chief of the Haemophilia Journal.

His main research interests lie in the area of haemostasis and thrombosis, especially clinical studies on the treatment modalities and the wide spectrum of complications of haemophilia in both developed and developing countries, as well as new anticoagulants and the management of thrombosis.

Prof. Dr. Mohamad Mohty
Hospital Saint-Antoine & University Pierre & Marie Curie - Paris, France

Mohamad Mohty is full Professor of Hematology and head of the Hematology and cellular therapy Department at the Saint-Antoine Hospital and Sorbonne University (Paris, France). Professor Mohty obtained his medical degree from the University of Montpellier, France, and his PhD from the University of Marseille, France. He also undertook post-doctoral work at the Hematology Department, Imperial College, Hammersmith Hospital, London, UK.

Professor Mohty is also head of a translational research team (INSERM team N°7) at the Saint-Antoine Research centre in Paris and his research is focused on the pathophysiology and immunobiology of normal and pathological antigen-presenting cells, especially the impact of novel immunomodulatory agents such as proteasome inhibitors, IMiDs and hypomethylating agents.

He has a special clinical focus on the development of reduced-toxicity conditioning regimens, immunotherapy and different aspects of therapy of acute leukemia and multiple myeloma.

Professor Mohty is past-president of the European Society for Blood and Marrow Transplantation (EBMT), and the current chairman of the Acute Leukemia Working Party of EBMT. He is also the founder and chairman of the “International Academy for Clinical Hematology (IACH; http://clinical-hematology.org/). He serves on the board of the EBMT, and the “Intergroupe Francophone du Myelome” (IFM). He is a member of the American Society of Hematology, American Society for Clinical Oncology, American Society for Blood and Marrow Transplantation, European Hematology Association, and EBMT.

Professor Mohty has published more than 550 peer-reviewed articles (https://www.ncbi.nlm.nih.gov/pubmed/?term=MOHTY+M) in the field of stem cell transplantation, leukemia and myeloma, in different hematology and immunology journals. He also serves as Editor-in-Chief of the journal Bone Marrow Transplantation, as Associate Editor for Leukemia, European Journal of Haematology and Blood Cancer Journal, as member of the editorial board of Haematologica, and as a regular reviewer in different immunology, hematology, and cancer journals such as the New Engl. J Med, Blood, J Clin Oncol, The Lancet, Lancet Oncology, Lancet Haematology, Nature Reviews, etc.

Dr. Irene Motta
University of Milan - Milan, Italy

Irene Motta is assistant professor at the Department of Clinical Sciences and Community Health at the University of Milan. She has clinical activities at the General Medicine and Rare Diseases Unit of the “Ca’ Granda Ospedale Maggiore Policlinico” Foundation in Milan. The Foundation is a scientific Institute for Research, Hospitalization and Health Care (IRCCS).

She is regularly invited as speaker at national and international educational events. Dr Motta is a member of the Italian Society of Internal Medicine (SIMI) and the Italian Society of Thalassemia and Hemoglobinopathies (SITE) and acts as reviewer for the American Journal of Hematology as well as the journal on Internal and Emergency Medicine.

Dr. François Provôt
Hôpital Claude Huriez & Lille University Hospital - Lille, France

François Provôt is a nephrologist at the Lille University center since 1999. He works in the kidney transplant and dialysis/apheresis department. He is the head of the TMA competence center in the North of France and works closely with Pr Paul Coppo (TMA national reference center in Paris).

Prof. Dr. Ann Janssens
University Hospital Leuven & Catholic University of Leuven, Belgium

Ann Janssens is Head of Clinics in the Department of Hematology at Leuven University Hospital, Leuven, Belgium. She obtained her medical degree from the University of Ghent, before specializing there in hematology. In vitro apoptosis and clonal evolution in chronic lymphocytic leukemia (CLL) was the title of her doctoral thesis.

Prof. Janssens has a special interest in CLL and other indolent lymphomas and also in immune thrombocytopenias (ITP). She acts as a co-ordinator for Phase I–IV clinical studies relating to CLL-low grade lymphomas and ITP. She has published in several peer-reviewed journals. She is a member of the editorial board of The Belgian Journal of Hematology. Since 2019 she is the President of the Belgian Hematological Society.

Prof. Dr. Tessa Kerre
Ghent University Hospital & Ghent University, Belgium

Since 2006, Prof. Dr. Tessa Kerre is staff member at the Department of Hematology at Ghent University Hospital, Belgium, Senior Clinical Investigator of the Research Foundation Flanders (FWO) and Clinical director of the adult stem cell transplant and cel​l therapy unit at the Ghent University Hospital. Since 2017, she is a Programme Director of the stem cell transplant programme at the Ghent University Hospital.

Prof. Dr Kerre is regularly invited to give lectures in national and international conferences. She has authored more than 75 papers in international journals and is currently involved as Principal Investigator in several clinical trials.

Prof. Dr. Catherine Lambert
Saint-Luc University Hospital & Catholic University of Louvain, Belgium

Catherine Lambert is an adult hematologist currently working at the Division of Hematology, Cliniques Universitaires Saint-Luc in Brussels, Belgium. Her main fields of interest are hemophilia and other bleeding disorders, thrombosis, clinical apheresis, sickle cell anaemia, thrombotic microangiopathy and immune thrombocytopenia.

Dr Lambert is the local director of the Joint Accreditation Committee – International Society for Cellular Therapy & European Society for Blood and Marrow Transplantation (JACIE) programme. She is actively involved in the World Federation of Hemophilia (WFH) Twinning Program and collaborates with the haemophilia treatment centre of Abidjan in the Ivory Coast. Dr Lambert is carrying out clinical research in the field of haemophilia care in developing countries.

Dr. Philip Maes
Antwerp University Hospital, Belgium

Philip Maes is hematologist and oncologist active as senior resident pediatrician at the University Hospital of Antwerp (UZA). He is specialized in benign and malignant hematology and hemostasis, hemophilia and HIV in children. He is a founder UPOCA (University Pediatric Oncologic Center of Antwerp) at UZA, founder of a Red Blood Cell Clinic at UZA and co-founder of the Hemophilia Treatment Center of Antwerp at UZA.

Dr. Sylvia Snauwaert 
AZ Sint-Jan Brugge, Belgium

Dr. Snauwaert has a special interest in lymphopoiesis, lymphoproliferative disorders and immunotherapy in hematopoietic malignancies. She is a member of the Belgian Haematological Society (BHS) and of the Lymphoproliferative Disorder subcommittee of the BHS (since January 2017). She is a member of the council of the ‘Wetenschappelijk Fonds Hematologie v.z.w. AZ Sint-Jan AV Brugge-Oostende’. She is a member of the LYSA. In October 2017 Dr. Snauwaert started as a senior physician in the AZ Sint-Jan AV Brugge-Oostende, where her clinical practice is focused on lymphoproliferative disorders, targeted therapies and coagulopathies. 

Dr. Ulf-Henrik Mellqvist
South Elvsborg Hospital, Sweden

Dr. Mellqvist is senior consultant at Department of Haematology Sahlgrenska University Hospital since 2001, Head of Sections of Haematology, Oncology and pulmonary disorders South Elvsborg Hospital since 2015. 

He graduated in 1989 at Gothenburg University, Gothenburg, Sweden, and did a post-graduate speciality in Internal Medicine in1995 Sahlgrenska University Hospital and in Hematology in 1997 Sahlgrenska University Hospital.

Dr. Mellqvist was chairman of the Swedish Diagnostic group for plasma cell disorders 2009-2014, Chairman of the Nordic Myeloma Study Group 2010-2012, President of the Swedish Haematology Association from 2014-2016. Today he is a member of the International Myeloma Working Group, Member of the International Myeloma Society, Member of the European Myeloma Network, Member of the American Society of Haematology and Member of the American Society of Clinical Oncology. 

Prof. Dr. Henrik Frederiksen
Department of Clinical Research, University of Southern Denmark

Dr. Fredriksen is Consultant Haematologist at the Department of Haematology, Odense University Hospital and Professor in Haematology at the Clinical Institute of the Southern Denmark University (SDU) where he obtained his Ph.D. in genetic epidemiology after graduating in Medical research from the Odense University.

In addition to being President of the Danish Society of Haematology since 2017 and vice chairman of the scientific council in the Danish Comprehensive Cancer Center since 2020, Dr. Frederiksen is also member of different scientific boards and study groups.

He supervises post-graduate doctorates, PhD studies and besides being the author of numerous publications, he regularly reviews publications and articles for Lancet Haematology, American Journal of Haematology and other related medical journals.

Dr. Fredriksen has also been the principal investigator for several clinical trials in haematology, including chronic lymphocytic leukemia, idiopathic thrombocytopenic purpura and myelodysplastic syndromes.